Published in Diabetes on August 01, 2001
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet (2009) 3.07
The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes (2008) 2.65
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology (2011) 1.79
Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia (2011) 1.27
Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia (2009) 1.15
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Proteomic changes associated with diabetes in the BB-DP rat. Am J Physiol Endocrinol Metab (2008) 1.05
Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol (2011) 1.04
Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. J Clin Invest (2011) 1.03
Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study. PLoS One (2010) 1.03
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis (2015) 1.02
Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr (2008) 0.94
Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans. J Biol Chem (2011) 0.91
Glucokinase regulatory protein gene polymorphism affects postprandial lipemic response in a dietary intervention study. Hum Genet (2009) 0.90
Pediatric fatty liver disease: role of ethnicity and genetics. World J Gastroenterol (2014) 0.90
The genetics of insulin resistance: Where's Waldo? Curr Diab Rep (2010) 0.89
Associations of common polymorphisms in GCKR with type 2 diabetes and related traits in a Han Chinese population: a case-control study. BMC Med Genet (2011) 0.86
Molecular targeting of pancreatic disorders. World J Surg (2005) 0.81
Functional characterization of MODY2 mutations highlights the importance of the fine-tuning of glucokinase and its role in glucose sensing. PLoS One (2012) 0.81
Insights into the Genetic Susceptibility to Type 2 Diabetes from Genome-Wide Association Studies of Obesity-Related Traits. Curr Diab Rep (2015) 0.81
Evolution of hepatic glucose metabolism: liver-specific glucokinase deficiency explained by parallel loss of the gene for glucokinase regulatory protein (GCKR). PLoS One (2013) 0.80
Insulin-receptor substrate-2 (irs-2) is required for maintaining glucokinase and glucokinase regulatory protein expression in mouse liver. PLoS One (2013) 0.78
Polymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke. Int J Clin Exp Med (2015) 0.77
Role of glucokinase in the subcellular localization of glucokinase regulatory protein. Int J Mol Sci (2015) 0.76
Identification of a sequence element on the 3' side of AAUAAA which is necessary for simian virus 40 late mRNA 3'-end processing. Mol Cell Biol (1985) 2.68
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet (1993) 2.31
Design of retrovirus vectors for transfer and expression of the human beta-globin gene. J Virol (1988) 2.06
Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med (1988) 1.87
Catalytically important domains of rat carnitine palmitoyltransferase II as determined by site-directed mutagenesis and chemical modification. Evidence for a critical histidine residue. J Biol Chem (1994) 1.37
Circumvention of immunity to the adenovirus major coat protein hexon. J Virol (1998) 1.26
Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther (1996) 1.25
Solubilization, purification, and characterization of a truncated form of rat hepatic squalene synthetase. J Biol Chem (1992) 1.22
Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci (1999) 1.18
Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol (1999) 1.15
Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood (1998) 1.12
An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol Dis (1998) 1.12
Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Infect Control (1984) 1.11
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene (1992) 1.09
Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Hum Gene Ther (1990) 1.07
c phosphorylation and activation of the IGF-I receptor in src-transformed cells. J Biol Chem (1994) 1.07
Multiplex sequencing of 1.5 Mb of the Mycobacterium leprae genome. Genome Res (1997) 1.05
Sustained expression of therapeutic levels of human factor VIII in mice. Blood (1996) 1.03
Characterization of the U3 and U6 snRNA genes from wheat: U3 snRNA genes in monocot plants are transcribed by RNA polymerase III. Plant Mol Biol (1992) 1.01
Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. Diabetes (2001) 1.00
In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther (1995) 0.95
Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood (1996) 0.93
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther (2000) 0.91
Characterisation and expression of a maize U3 snRNA gene. Biochim Biophys Acta (1994) 0.90
In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther (2000) 0.90
Screening for abdominal aortic aneurysms in a hypertensive patient population. Arch Intern Med (1996) 0.90
Hepatic transplantation in children under 3 months of age: a single centre's experience. J Pediatr Surg (1997) 0.89
High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther (1996) 0.89
Type-1 insulin-like growth factor receptor overexpression produces dual effects on myoblast proliferation and differentiation. J Cell Physiol (1994) 0.89
Covalent modification of the active site of carbamyl phosphate synthetase by 5'-p-fluorosulfonylbenzoyladenosine. Direct evidence for two functionally different ATP-binding sites. J Biol Chem (1980) 0.89
Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther (2001) 0.89
Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion. Hum Gene Ther (2001) 0.88
Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum Gene Ther (1999) 0.87
Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Ann N Y Acad Sci (1999) 0.87
Differential expression of U5snRNA gene variants in maize (Zea mays) protoplasts. Plant Mol Biol (1993) 0.86
Synthesis of adenoviral targeting molecules by intein-mediated protein ligation. Gene Ther (2003) 0.86
Natural methods of protein stabilization: thermostable biocatalysts. Biochem Soc Trans (2007) 0.86
Overexpression, purification, and kinetic characterization of a carboxyl-terminal-truncated yeast squalene synthetase. Arch Biochem Biophys (1993) 0.86
Talonavicular coalition. Objective gait analysis. J Am Podiatr Med Assoc (1993) 0.85
Membrane sites regulating developmental gene expression in Dictyostelium discoideum. Cell (1982) 0.84
The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia (2002) 0.83
In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther (1999) 0.82
Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems. Arch Biochem Biophys (1995) 0.81
Ligand-dependent inhibition of myoblast differentiation by overexpression of the type-1 insulin-like growth factor receptor. J Cell Physiol (1993) 0.80
Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic acid: existence of novel and expected binding modes. J Mol Biol (1996) 0.78
Gene therapy for hemophilia A. Thromb Haemost (1997) 0.78
Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. J Biol Chem (1994) 0.78
Multivalent cations and ligand affinity of the type 1 insulin-like growth factor receptor on P2A2-LISN muscle cells. J Cell Physiol (1998) 0.77
In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector. Haemophilia (1999) 0.77
Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules. Thromb Haemost (1999) 0.76
Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Thromb Haemost (1999) 0.76
Our experience on Actovegin, is it cutting edge? Int J Sports Med (2011) 0.76
Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. Haemophilia (1999) 0.75
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab (2009) 0.75
Tendon transfers in the paralytic hip. J Bone Joint Surg Am (1979) 0.75
Complex health problems. Clinically assessing self-management abilities. J Gerontol Nurs (1991) 0.75
Teaching and evaluating synthesis in an associate degree nursing program--a developmental experience. League Exch (1975) 0.75
The 1995 Non-profit Software Directory. Fund Raising Manage (1995) 0.75
Haemophilia A gene therapy. Haemophilia (1998) 0.75